Background: Antifungal prophylaxis may result in breakthrough infections in hematology patients with severe agranulocytosis, with few studies assessing risk factors and clinical outcomes of breakthrough candidemia. We described the distribution of Candida species, assessed risk factors for mortality in such patients, and determined differences in the incidence and mortality of breakthrough candidemia between patients who did or did not receive an allogeneic hematopoietic stem cell transplant.
Methods: We collected clinical and microbiological data of patients with hematologic malignancies and breakthrough candidemia from a single center. Seven-day and 30-day follow-up outcomes were recorded; the incidence and mortality of breakthrough candidemia between patients who did or did not undergo an allogeneic transplant were compared. Kaplan-Meier survival estimates were used to generate survival curves, and predictors were identified using Cox regression analyses.
Results: Of 71 enrolled patients, 17 received allogeneic transplants. Incidences of breakthrough candidemia were 17 of 2924 (0.58%) and 54 of 12 015 (0.45%) in the transplant and nontransplant groups, respectively (P = .35). The most common isolate was Candida tropicalis, and antifungal agent combinations were the most common first-line treatment. Cumulative mortality rates of patients were 21.1% and 31.0% at days 7 and 30, respectively, and they significantly differed between both groups. Septic shock, central venous catheter removal, and granulocyte recovery were significantly associated with 7-day mortality; the latter 2 remained independent predictors of 30-day mortality.
Conclusions: Breakthrough candidemia-related mortality was higher in the allogeneic transplant group, although the incidence was not significantly different between the groups. Prompt and adequate antifungal treatment with catheter removal may reduce mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciaa1523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology of Invasive Fungal Diseases: A 10-Year Experience in a Tertiary Pediatric Hematology-Oncology Department in Greece.
J Fungi (Basel)
July 2024
Department of Pediatric Hematology-Oncology & Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion & Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Article Synopsis
- Advances in pediatric cancer treatment have improved outcomes for infectious diseases, but invasive fungal diseases (IFDs) still pose significant health risks for high-risk patients.
- A retrospective study from 2013-2022 in Crete found a 7.8% prevalence of IFDs among pediatric patients, with the most common being invasive pulmonary aspergillosis and candidemia.
- Key risk factors for developing IFDs included prolonged ICU stay, extensive antimicrobial use, and fungal colonization, with an overall mortality rate of 16.7% among those affected.
Comparison of fungemia caused by Candida and non-Candida rare yeasts: a retrospective study from a tertiary care hospital.
Med Mycol
May 2024
Department of Public Health, Medical Faculty, Eskisehir Osmangazi University, 26040, Eskisehir, Turkey.
Article Synopsis
- Non-Candida rare yeasts (NCY) are being reported more as causes of serious infections called fungemia, even though Candida is more common.
- This study looked at patients with NCY fungemia compared to those with Candida fungemia to understand their differences and how they respond to antifungal treatments.
- It found that people with certain health problems, like blood cancers and weakened immune systems, are more likely to get infections from NCY, which is a growing concern, especially in hospitals.
Breakthrough Candida albicans bloodstream infection associated with in vivo development of pan-azole resistance related to ERG3 gene deletion.
Pathology
June 2024
Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, Westmead, NSW, Australia; Sydney ID, The University of Sydney, Sydney, NSW, Australia.
[Invasive candidiasis after hematopoietic cell transplantation].
Rinsho Ketsueki
October 2023
Division of Hematology, Jichi Medical University Saitama Medical Center.
Candida species are the second most frequent fungal pathogen of invasive fungal disease after hematopoietic cell transplantation (HCT) following Aspergillus species. Prolonged severe neutropenia and mucocutaneous barrier impairment resulting from the conditioning regimen or central venous catheter placement are major risk factors for invasive candidiasis in the early phase after HCT. Graft-versus-host disease (GVHD) and corticosteroid use affect the development of invasive candidiasis in the post-engraftment phase after allogeneic HCT.
View Article and Find Full Text PDFBreakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.
Med Mycol
June 2023
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Breakthrough candidemia (BrC) is a significant problem in immunocompromised patients, particularly those with hematological disorders. To assess the characteristics of BrC in patients with hematologic disease treated with novel antifungal agents, we collected clinical and microbiological information on said patients from 2009 to 2020 in our institution. Forty cases were identified, of which 29 (72.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!